Wire · opportunities
Clinical trial tests new way to treat common inherited heart disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
A Phase 3 randomized clinical trial led by Oregon Health & Science University shows that aficamten, a cardiac myosin inhibitor developed by Cytokinetics, significantly improves exercise capacity and quality of life for patients with nonobstructive hypertrophic cardiomyopathy, an inherited heart disease affecting 1 in 350 people worldwide.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Aficamten’s success opens a new treatment avenue for nonobstructive hypertrophic cardiomyopathy, signalling opportunity for biotech founders in cardiac drugs to accelerate development and market access efforts. You should connect with cardiologists and patients now to position your therapy as a critical alternative in an underserved market segment.
◆ Coverage
1 source · 28 Aug 2026
◆ Related on Wire
◆ Topics